Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for CD69 and provides a CD69-binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QK X21AFKX25X26LKD. The present disclosure also relates to the use of such a CD69-binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

Abstract: A method of operating a wireless device in a wireless communication network. The method includes transmitting, to a network node, control information in a signaling structure, the signaling structure comprising a content header, the content header being indicative of size and/or type of one or more control information substructures of the signaling structure. The disclosure also pertains to related devices and methods.

Abstract: A method of operating a wireless device in a wireless communication network. The wireless device is configured for communicating with a first transmission source, and for receiving synchronisation signaling from a second transmission source, wherein communicating with the first transmission source is based on a gap time interval between communication signaling and synchronisation signaling associated to the first transmission source. The disclosure also pertains to related devices and methods.

Abstract: There is disclosed a method of operating a radio node in a wireless communication network. The method includes communicating utilising data signaling carrying a data block having a data block size, wherein the data signaling starts in time domain at a starting allocation unit, the data block size being dependent on a position in time domain on a reference allocation unit associated to reference signaling, the reference allocation unit trailing the starting allocation unit in time domain. The disclosure also pertains to related devices and methods.

Abstract: The present disclosure provides a bioreactor for extracting cell-derived products from cultured cells, the bioreactor comprising a container, an inlet for inputting cell culture medium into the container, an outlet for outputting cell culture medium comprising cell-derived products from the container, the container comprising, or being connected to, a compartment comprising nanostructured cellulose configured to receive cells, said compartment comprising a first separating surface separating the nanostructured cellulose from the outlet and allowing cell culture medium comprising cell-derived products to pass through the first separating surface. The present disclosure also provides a method for separating cell-derived products from cultured cells and a nanostructured cellulose product.

Abstract: A detection and reporting device for determining a usage event indicating a use of a piece of hygiene equipment, the detection and reporting device comprising a positioning section that allows determining positional information indicating a position of the detection and reporting device; a sensor section configured to sense over a time span an observable indicating a use of the piece of hygiene equipment and to generate usage event information on the basis of the sensed observable; and a reporting section configured to generate and transmit a message on the basis of said usage event information and on information allowing an association to said positional information.

Abstract: A pharmaceutical composition for anti-viral treatment for papillomavirus associated diseases in mammals, comprising a therapeutically effective amount of Ovatodiolide or Ovatodiolide related substances or an enriched plant extract containing anisomelic acid and ovatiodiolide. The pharmaceutical composition may comprise Ovatodiolide or Ovatodiolide related substances or the enriched extract in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvent or surfactant or a combination thereof. A method of treating or preventing papillomavirus associated diseases in a mammal is also provided.

Abstract: A detection and reporting device for determining a usage event indicating a use of a piece of hygiene equipment, the detection and reporting device comprising a positioning section that allows determining positional information indicating a position of the detection and reporting device; a sensor section configured to sense over a time span an observable indicating a use of the piece of hygiene equipment and to generate usage event information on the basis of the sensed observable; and a reporting section configured to generate and transmit a message on the basis of said usage event information and on information allowing an association to said positional information.

Abstract: A detection and reporting device for determining a usage event indicating a use of a piece of hygiene equipment, the detection and reporting device comprising a positioning section that allows determining positional information indicating a position of the detection and reporting device; a sensor section configured to sense over a time span an observable indicating a use of the piece of hygiene equipment and to generate usage event information on the basis of the sensed observable; and a reporting section configured to generate and transmit a message on the basis of said usage event information and on information allowing an association to said positional information.

Abstract: A detection and reporting device for determining a usage event indicating a use of a piece of hygiene equipment, the detection and reporting device comprising a positioning section that allows determining positional information indicating a position of the detection and reporting device; a sensor section configured to sense over a time span an observable indicating a use of the piece of hygiene equipment and to generate usage event information on the basis of the sensed observable; and a reporting section configured to generate and transmit a message on the basis of said usage event information and on information allowing an association to said positional information.

Abstract: Functionalized substrates with properties that can control cell-substrate interactions, induce cellular processes and decisions by means of passive and active control to enhance cell proliferation, cell migration and wound healing are provided. By including a sensing electrode on the substrate, it is possible to measure the metabolites of cells or follow the migration of additives like drug molecules in real-time. The present technology provides a new cell culture and imaging platform composed of a transparent and chemically and topographically customized latex film with electrodes that enable real-time measurement of e.g. pH and ion concentration in the cell medium as well as the metabolic states of the cells.

Abstract: The invention is based on a finding that silencing PME-1 gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions.

Abstract: Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.

Abstract: Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.

Abstract: A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided.

Abstract: The invention is based on a finding that silencing PME-1 gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions.

Abstract: Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.

Abstract: The present invention concerns a procedure and a system for feeding optical fiber cables into a pipeline with the help of an installation device at adjustable speed. In order to prevent damage during the advancement of the optical fiber cable the engine (15) of the installation device has been supplied with a friction safety clutch (17) exerting pressure on a moving coil (18, 23).

Abstract: The invention relates to a method of inhibiting myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan, where said lignan is enterolactone. The invention is further directed to a method inhibiting myeloperoxidase activity or oxidative burst of macrophages in an individual by administering to the individual an effective amount of a lignan where said lignan is enterolactone or hydroxymatairesinol or a mixture. Finally, the invention is directed to a method of inhibiting oxidative burst or myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan which is hydroxymatairesinol.

Abstract: The present invention concerns a procedure and a system for feeding optical fibre cables into a pipeline with the help of an installation device at adjustable speed. In order to prevent damage during the advancement of the optical fibre cable the engine (15) of the installation device has been supplied with a friction safety clutch (17) exerting pressure on a moving coil (18, 23).